Home › Funds › ACT CAPITAL MANAGEMENT, LLC › CYTK
ACT CAPITAL MANAGEMENT, LLC position in CYTK
CYTOKINETICS INC · Health Care
ACT CAPITAL MANAGEMENT, LLC reported holding 47,500 shares of CYTK (CYTOKINETICS INC) in its Q2 2026 13F filing — a position valued at US$4.0M, representing 2.64% of its reported portfolio and ranking #11 among its reported holdings. ACT CAPITAL MANAGEMENT, LLC has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACT CAPITAL MANAGEMENT, LLC's CYTK position evolved
ACT CAPITAL MANAGEMENT, LLC first disclosed a stake in CYTK in Q4 2025 at 64,500 shares (US$4.1M). The position peaked in Q1 2026 at 64,500 shares, worth US$4.3M. Across 3 filings, ACT CAPITAL MANAGEMENT, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 47,500 shares valued at US$4.0M — a reduction of -17,000 shares quarter over quarter.. Notable position changes include a 26% trim in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 64.50K | $4.10M | New |
| Q1 2026 | 64.50K | $4.25M | Hold |
| Q2 2026 | 47.50K | $4.05M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
More on ACT CAPITAL MANAGEMENT, LLC
FAQ
How long has ACT CAPITAL MANAGEMENT, LLC held CYTK?
ACT CAPITAL MANAGEMENT, LLC has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ACT CAPITAL MANAGEMENT, LLC's current position in CYTK?
As of Q2 2026, ACT CAPITAL MANAGEMENT, LLC holds 47.50K shares of CYTK (CYTOKINETICS INC), valued at $4.05M, representing 2.64% of its reported portfolio and ranking #11.
Has ACT CAPITAL MANAGEMENT, LLC been buying or selling CYTK?
In the latest 13F filing (Q2 2026), ACT CAPITAL MANAGEMENT, LLC reduced its position in CYTK. The position peaked in Q1 2026 at 64.50K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.